$GH

Kalia Kumud purchased $78K of GH

Kalia Kumud (Chief Information Officer) purchased 600 shares of Guardant Health, Inc. (GH) at $130.76 on 2026-06-15.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 30, 2026, 9:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Bullish
medium confidence
Mentioned
$GH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHBullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase by the company’s CIO, which may slightly influence sentiment but is not a fundamental update.

02

Market read

Traders may note the insider buy as a small positive sentiment datapoint, but it is unlikely to drive a major repricing alone.

03

What to watch

The filing does not indicate intent beyond the disclosed buy; without follow-on buys/sells or a larger transaction size, signal strength is limited.

Relevance 4/10Novelty 5/10Timing: new Form 4 filed 2026-06-30 (covers 2026-06-15 purchase)

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHBullishMedium confidence
Context

Guardant Health CIO Kalia Kumud filed a Form 4 open-market purchase of 600 shares at $130.76 on 2026-06-15.

Expected impact

Likely limited near-term impact; any reaction would be small and short-lived unless followed by additional disclosures.

Evidence & confidence

The transaction is a routine officer open-market buy (no 10b5-1 plan), but the dollar size (~$78k) is not large enough to be a standalone catalyst.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Officer purchases can be driven by personal liquidity needs, diversification, or routine compensation-related activity rather than a strong forward view.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Kalia Kumud

    Chief Information Officer who purchased 600 shares open-market at $130.76.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.